Sign in

    Brett Larson

    Research Analyst at Leerink Partners

    Brett Larson is an Equity Research Analyst at Leerink Partners specializing in small and mid cap biotechnology companies, where he provides in-depth analysis and coverage within the healthcare sector. He has covered publicly traded biotech firms including Zafgen (ZFGN), and leverages a background in life sciences consulting from Trinity Partners as well as academic research at the University of Vermont College of Medicine. Larson started his career in biotech strategy consulting before joining Leerink, bringing several years of industry experience to his analyst role. He holds a bachelor's degree from Amherst College, and his research is recognized for its differentiated, proprietary focus on the biotech space.

    Brett Larson's questions to ZFGN leadership

    Brett Larson's questions to ZFGN leadership • Q4 2015

    Question

    Brett Larson of Leerink Partners inquired about the specific path forward for beloranib following the submission of the risk mitigation data package to the FDA, including potential timelines for lifting the clinical hold and whether updates on other pipeline programs would be paused.

    Answer

    CEO Tom Hughes explained that Zafgen has an agreement with the FDA on the content for the briefing book and expects the process of meeting and receiving feedback to take a "series of months." He clarified there is no special quiet period, just standard FDA procedure timing. Hughes also stated that updates on other programs would be provided once there is clarity from the FDA, which could occur before the hold is formally lifted.

    Ask Fintool Equity Research AI